| Role |
Name |
Disclosure |
Details |
| Author | Nicholas J Sarlis, MBBS, MD, PhD, FACP, Medical Director, Department of Oncology-US Medical Affairs Department, Sanofi-Aventis Pharmaceuticals | Nothing to disclose | Details | | Coauthor | Boaz Hirshberg, MD, Associate Director, CVMD, Pfizer | Nothing to disclose | Details | | Medical Editor | Harris C Taylor, MD, Chief, Division of Endocrinology, Department of Internal Medicine, Lutheran Medical Center of Cleveland; Clinical Professor, Case Western University School Of Medicine | Nothing to disclose | Details | | Pharmacy Editor | Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine | Nothing to disclose | Details | | Managing Editor | Kent Wehmeier, MD, Professor, Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism, St Louis University School of Medicine | Nothing to disclose | Details | | CME Editor | Mark Cooper, MD, Head, Vascular Division, Baker Medical Research Institute; Professor of Medicine, Monash University | Nothing to disclose | Details | | Chief Editor | George T Griffing, MD, Professor of Medicine, Director of General Internal Medicine, St Louis University | Nothing to disclose | Details |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Boaz Hirshberg, Coauthor |
The contributor discloses no conflict of interest. |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Harris C Taylor, Medical Editor |
The contributor discloses no conflict of interest. |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Kent Wehmeier, Managing Editor |
The contributor discloses no conflict of interest. |
|